In clinical research, scale is typically achieved through standardization. Processes are tightened, variation is reduced, and operational efficiency becomes the ultimate goal. But what if scale did not have to eliminate individuality? What if personalization itself could be engineered, structured, and delivered reliably?
For Volodymyr Rogoznyi, founder of NeSPaT, this question has shaped both his philosophy and his company’s trajectory. “Scaling healthcare does not require sacrificing humanity,” he says. “Human-centered design can be systematized and scaled.” That belief runs counter to conventional thinking in clinical trial logistics, where deviation from protocol is often viewed as risk. Yet Volodymyr has built his business precisely on disciplined deviation, combining structured processes, strategic governance, and technology with deep respect for patients as individuals.
From Entrepreneurial Instinct to Strategic Positioning
Rogoznyi’s entrepreneurial path began during a period of economic instability in Ukraine. Early in his career, he entered cross-border trade across Eastern Europe, learning firsthand how pricing works, how negotiations unfold under pressure, and how fragile working capital can be. That experience became his practical business education.
Over time, he built companies in business travel and marketing events. These ventures were operationally complex, requiring precision, timing, and accountability. But by 2017, after completing his MBA, his mindset shifted from opportunistic growth to strategic positioning. He began looking for industries where standards were still forming, markets where operational maturity could become a decisive advantage.
The clinical research sector in Ukraine was at precisely that stage. Western pharmaceutical companies were opening offices, and international CROs were establishing local branches. The ecosystem was young and fragmented, but clearly poised for expansion.
Rather than entering broadly, Rogoznyi identified a specific operational gap: clinical trial patient travel and reimbursement services.
Engineering Customization at Scale
The insight was simple but unconventional. Rogoznyi and his team had deep experience organizing complex, high-touch travel for corporate executives. What if those same concierge-level standards, precision, proactive communication, and accountability were applied to patients participating in clinical trials?
In practice, this meant treating patients not as logistical units, but as people navigating vulnerable moments in their lives. Clinical trial participation often involves uncertainty, physical strain, and emotional stress. A missed ride or reimbursement delay is not merely inconvenient—it can disrupt treatment schedules and trial integrity.
While many service providers pursue scale through rigid standardization, Rogoznyi chose a different path.
“We do not simply standardize services, we scale individualized ones,” he says.
Every patient arrives with different medical conditions, geographic realities, financial constraints, and emotional needs. NeSPaT’s model focuses on building structured systems that allow for flexibility and on clear processes that support personalization rather than suppress it.
This balance between structure and flexibility has become the company’s defining principle. Strategy is not treated as an annual exercise but as a continuous process of reassessment. When the industry rushes toward total automation, Rogoznyi asks how technology can enhance human judgment rather than replace it.
The results have been measurable. NeSPaT expanded across multiple European markets, strengthened its governance model by transitioning key managers into equity partners, and scaled operations significantly year over year. Rather than growing through aggressive marketing alone, the company earned trust among established CROs and sponsors by reducing operational disruption and increasing reliability.
Expanding Across Borders Without Losing Focus
The most significant test came during wartime in Ukraine. Preserving operations while simultaneously expanding into Europe required disciplined governance and leadership presence. Rogoznyi made a deliberate decision: markets cannot be built remotely. He entered new regions personally, ensuring alignment, cultural understanding, and partnership development.
This philosophy carried into the company’s expansion into the United States. Launching NeSPaT in Texas alongside American partner Laura Van Vessem-Goodley meant building from zero—defining positioning, forming the team, adapting processes, and establishing credibility in a highly competitive healthcare environment.
In 2025, NeSPaT was shortlisted as Best Foreign Startup at the Texas A-List Awards, an early validation of its model in the U.S. market.
Technology now plays an increasingly important role in the company’s operations. AI-driven tools are being developed to enhance routing accuracy, reporting precision, and order processing speed. But Rogoznyi remains pragmatic.
“Technology is an instrument,” he says. “The value is still in people.”
For him, patient-centricity is a foundational principle, not a marketing slogan. In clinical research support services, operational details directly influence whether patients remain compliant with study protocols. Behind every itinerary, reimbursement form, and transport coordination is a human life.
As decentralized trials expand and healthcare operations grow more complex, the pressure to standardize will only intensify. Rogoznyi’s model suggests a different possibility: that competitive advantage in clinical trial logistics may come not from eliminating variation, but from designing systems capable of handling it intelligently.
He believes that even as NeSPaT’s services scale internationally, they must remain deeply human at their core, preserving empathy, trust, and personal connection.
And in an industry built on protocols and precision, that may be exactly the edge that defines the next phase of patient-centric clinical research.
